Songul Kucukcelebi

Ms. Songul Kucukcelebi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
SKSongul Kucukcelebi
Songul Kucukcelebi
FLFreek R. van ‘T Land
Freek R. van ‘T Land
Sjoerd H. van der BurgSjoerd H. van der Burg
Sjoerd H. van der Burg
FEFerry A. L. M. Eskens
Ferry A. L. M. Eskens
MHMarjolein Y. V. Homs
Marjolein Y. V. Homs
Casper Van EijckCasper Van Eijck
Casper Van Eijck
In pancreatic ductal adenocarcinoma (PDAC), the dense desmoplastic stroma and insufficient infiltrating T cells represent a significant barrier to effective immunotherapy. In this phase I, dose-escalation study, previously registered at the Dutch Trial Register and later on at ClinicalTrial (NCT05650918), we administer an autologous dendritic cell (DC) vaccine (MesoPher) with an agonistic CD40-specific antibody (mitazalimab) to metastatic PDAC patients (n = 16) after (m)FOLFIRINOX treatment. We included patients with WHO performance status 0-1 with accessible metastatic lesions, and excluded patients with history of previous immunotherapy or malignant ascites. Primary objectives include safety and tolerability. Immune modulation and clinical outcomes are monitored as secondary objectives. MesoPher (25 × 106 DCs) is co-administered with 300, 600, or 1200 μg/kg mitazalimab. MesoPher/mitazalimab therapy is safe and well-tolerated, and the primary endpoint is met. One transient dose-limiting toxicity (DLT) is observed (grade 3 fever). MesoPher/mitazalimab induces a systemic increase in activated and vaccine-specific T cell responses. In post-therapy tumor biopsies, increased T cell infiltration and decreased collagen deposition are observed. No objective radiological response is observed, but eight patients (50%) show stable disease after three administrations. In conclusion, MesoPher/mitazalimab combination therapy is safe and tolerable in patients with metastatic PDAC and enhances systemic immune activation and local immune responses. Future research should evaluate the efficacy of this promising approach as maintenance therapy shortly after completing chemotherapy.

15 March 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Casper Van EijckCasper Van Eijck
Casper Van Eijck
HHHassana el Haddaoui
Hassana el Haddaoui
SKSongul Kucukcelebi
Songul Kucukcelebi
DVDisha Vadgama
Disha Vadgama
AFAmine Fellah
Amine Fellah
MWMarcella Willemsen
Marcella Willemsen
Purpose: Amid the need for new approaches to improve survival in pancreatic ductal adenocarcinoma (PDAC), immune-based therapies have garnered interest. Rintatolimod, a Toll-like receptor 3 (TLR-3) agonist, is a potential candidate due to its dual impact on restraining PDAC cell functions and boosting the antitumor immune response. This study investigates the effect of TLR-3 activation through rintatolimod on the peripheral immune landscape of patients with advanced PDAC. Experimental Design: Paired blood samples of 30 patients with advanced PDAC, collected at baseline and after 12 rintatolimod intravenous infusions, underwent comprehensive transcriptomic NanoString and proteomic flow cytometry profiling. The impact of rintatolimod and immunologic factors on survival outcomes was assessed through univariate Cox proportional hazards models. Results: Rintatolimod treatment enhances peripheral immune activity at the transcriptomic and proteomic levels, particularly involving type 1 conventional dendritic cells (cDC1) and T cells. Post-rintatolimod, the increased peripheral abundance of BTLA+ XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes. Patients with stable disease exhibited pronouncedDCand T-cell activation gene overexpression. Notably, the expression of immune checkpoints PD-L1 and PD-L2 decreased post-rintatolimod across all patients. However, those with progressive disease showed increased expression of genes encoding IDO1 and PD-1. Conclusions: This study presents compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through rintatolimod. Rintatolimod may break immunologic tolerance by enhancing antitumor immunity through DC-mediated Th-cell responses. Furthermore, our findings lay the groundwork for investigating the potential synergy between TLR-3 activation and immune checkpoint inhibitor therapy to improve therapeutic outcomes. See related commentary by Martínez-Riaño et al., p. 3355

15 August 2024
Verified
Other
Open access
PDF file
HHHassana el Haddaoui
Hassana el Haddaoui
SKSongul Kucukcelebi
Songul Kucukcelebi
DVDisha Vadgama
Disha Vadgama
AFAmine Fellah
Amine Fellah
Dana A.M. MustafaDana A.M. Mustafa
Dana A.M. Mustafa
MWMarcella Willemsen
Marcella Willemsen
Supplementary Figure S1. Gating strategy of flow cytometry analyses on blood samples. Two panels were designed to investigate the presence and activation of peripheral T cells, DCs, and myeloid cells. The top-row gating strategy was applied in all panels.

15 August 2024
Verified
Other
Open access
PDF file
HHHassana el Haddaoui
Hassana el Haddaoui
SKSongul Kucukcelebi
Songul Kucukcelebi
DVDisha Vadgama
Disha Vadgama
AFAmine Fellah
Amine Fellah
Dana A.M. MustafaDana A.M. Mustafa
Dana A.M. Mustafa
MWMarcella Willemsen
Marcella Willemsen
Supplementary Figure S2. Relative abundance of peripheral immune cells. (A-D) Boxplots illustrating the differences in immune cell scores between baseline and post-rintatolimod (A), between progressive disease and stable disease patients at baseline (B), between progressive disease and stable disease patients post-rintatolimod (C), and delta change between progressive disease and stable disease patients (D). The x-axis displays the different immune cell subsets, and the y-axis displays the immune cell score or delta immune cell score (upper right).

15 August 2024
Verified
Other
Open access
HHHassana el Haddaoui
Hassana el Haddaoui
SKSongul Kucukcelebi
Songul Kucukcelebi
DVDisha Vadgama
Disha Vadgama
AFAmine Fellah
Amine Fellah
Dana A.M. MustafaDana A.M. Mustafa
Dana A.M. Mustafa
MWMarcella Willemsen
Marcella Willemsen
Supplementary Table S1. Antibodies used for flow cytometry analyses. Supplementary Table S2. Selected marker genes to identify immune cell type in the transcriptomic NanoString analysis.Supplementary Table S3. Summary of sample inclusion in various immunoprofiling analyses.Supplementary Table S4. Treatment characteristics of the included PDAC patients (n = 30).Supplementary Table S5. Univariate Cox proportional hazards models for OS and PFS of the clinical covariates.Supplementary Table S6. Clinical and treatment characteristics of the PDAC patients included in the flow cytometry analysis.Supplementary Table S7. Pathway overrepresentation analyses of the transcriptomic NanoString analysis. Genes with significant overexpression (P < 0.01) in baseline samples compared to after 12 rintatolimod infusions are included.Supplementary Table S8. Univariate Cox proportional hazards models for OS and PFS of the NanoString immune cell counts.Supplementary Table S9. Transcriptomic NanoString (A, B) and flowcytometry (C) immunoprofiling analysis comparing patients receiving ≤ and > median of 10 FOLFIRINOX cycles.Supplementary Table S10. Transcriptomic NanoString (A, B) and flowcytometry (C) immunoprofiling analysis comparing patients who did receive and did not receive SBRT.

15 August 2024
Verified
Other
Open access
PDF file
HHHassana el Haddaoui
Hassana el Haddaoui
SKSongul Kucukcelebi
Songul Kucukcelebi
DVDisha Vadgama
Disha Vadgama
AFAmine Fellah
Amine Fellah
Dana A.M. MustafaDana A.M. Mustafa
Dana A.M. Mustafa
MWMarcella Willemsen
Marcella Willemsen
Supplementary Figure S3. Transcriptomic NanoString analysis for delta values (after mRNA counts – baseline mRNA counts). (A) t-SNE plot illustrates no apparent segregation of delta changes among 730 immune-related genes based on treatment response. (B) Boxplots displaying significant DE genes between stable and progressive disease patients upon rintatolimod treatment. The x-axis represents different genes, and the y-axis represents the log2 gene expression count.